Safety and efficacy of radioimmunotherapy (RIT) in treatment of non-Hodgkin's lymphoma in the community setting

90Y‐ibritumomab‐tiuxetan as a therapeutic alternative for follicular lymphoma (FL): A single‐center experience

“…The identified ratios correspond well to other published studies. Overall response rates for RIT varied from 80% to 95% and were consistently higher than 80% for rituximab in different therapeutic situations (Tables and ) . Respectively, complete remission rates varied between 50%‐76.9% and 69%‐72.5% following either radioimmunotherapy or rituximab therapy.…”

“…Following the approval of the human chimeric anti-CD20 antibody rituximab in 1997, immunotherapy has become a major therapeutic principle for FL patients. 11,23,27 Based on the anti-CD20 principle, targeted antibody therapy can result in a higher local penetration, especially in patients with bulky disease. 23 Hence, radioimmunoconjugates such as 90 Y-ibritumomab tiuxetan serve for therapeutic alternatives in patients with NHL B-cell malignancies.…”

“…The linkage of a particle‐emitting isotope radiotherapy targets tissue with presence of CD‐20‐expressing cells. In comparison with external beam radiation therapy, targeted antibody therapy can result in a higher local penetration, especially in patients with bulky disease …”

“…Furthermore, for patients with a low‐risk profile and with confirmed relapses including those for whom conventional chemotherapies are not feasible, radioimmunotherapy (RIT) offers an alternative therapeutic option …”

“…In comparison with external beam radiation therapy, targeted antibody therapy can result in a higher local penetration, especially in patients with bulky disease. 23 Furthermore, for patients with a low-risk profile and with confirmed relapses including those for whom conventional chemotherapies are not feasible, radioimmunotherapy (RIT) offers an alternative therapeutic option. 17,21,[23][24][25] To our knowledge, there are only few studies with focus on the comparative analysis of both therapeutic principles.…”